Overview
Lobbying Costs
750,000€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
1.75 Fte (3)
Lobbyists with EP accreditation
1
High-level Commission meetings
10
Lobbying Costs over the years
-
Info
Gilead Sciences (GILD)
EU Transparency Register
258845020786-10 First registered on 23 Feb 2016
Goals / Remit
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide.
Main EU files targeted
EU initiatives relevant to HIV/AIDS, Hepatitis B & C and oncology
- ATMP Regulation
- EU IP policy
- EU research policy
- EU trade policy
- Health Systems Performance Assessment
- Health Technology Assessment & Market Access
- Industrial policy
- Outcomes-based healthcare systems
- Orphan Medicinal Products Regulation
- Paediatric Regulation
- Digital Health
- Europe's Beating Cancer Plan
- Blood, tissues and cells legislation
- Sustainable Development GoalsAddress
Head Office
333 Lakeside
Foster City
California CA94404
UNITED STATESEU Office
Park Lane
Culliganlaan 2
Diegem 1831
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 100% 1 50% 1 25% 1 Lobbyists (Full time equivalent)
1.75
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
1 accreditations were / are live (in bold) for the selected state of 13 Feb 2020
Name Start date End Date William SCHARF 10 Oct 2023 09 Oct 2024 Andrea ZANAGLIO 12 Oct 2023 11 Oct 2024 Mr Andrea Zanaglio 12 Oct 2023 15 Apr 2024 Mr William SCHARF 10 Oct 2023 15 Apr 2024 Mr William SCHARF 12 Oct 2022 10 Oct 2023 Mr Andrea Zanaglio 12 Oct 2022 12 Oct 2023 Ms Claire Albano 31 Aug 2019 01 Sep 2020 Mr Davis MARK 16 Oct 2018 01 Nov 2019 Ms Claire Albano 12 Jun 2018 12 Jun 2019 Mr Davis MARK 20 Jul 2017 07 Jul 2018 Mr Julien Patris 20 Jul 2017 01 Dec 2017 Complementary Information
The Registry does not allow entering less than 25% of employees' working time. However a total of 6 Gilead employees are involved in covered activities with 4 of these employees working less than 10% on covered activities, making up a total of 6 persons involved, equivalent to approx. 1.8% FTE as indicated above.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
AMCHAM EU: http://www.amchameu.eu
Europabio http://www.europabio.org
EUCOPE http://www.eucope.orgMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
750,000€
Other financial info
This estimate includes costs attributable to covered activities, including consulting fees, meeting costs and the pro rata salary and travel costs of Gilead Sciences' staff involved in representation to the European institutions, based on the proportion of employee time spent on these activities.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
Support to and participation in multi-stakeholder initiatives advocating for policy initiatives towards elimination of hepatitis C, promoting improved long term health outcomes for people living with HIV and exploring policy options to improve access to ATMPs across Europe;
An initiative with AMCHAM EU to identify policy options to improve the environment for life sciences innovation in the EU.
Sponsorship of a journalistic investigation on HIV independently carried out by POLITICO Europe.Other activities
None declared
- Meetings
Meetings
10 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 22 Mar 2023 Location Brussels Subject Discussed Gilead’s manufacturing operations in Ireland and globally. Gilead outlined their concerns with the soon to be published EU Pharmaceutical strategy, with particular emphasis on unmet medical needs, regulatory data protection and innovation Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Patricia Reilly (Cabinet member)
-
Date 11 Jun 2021 Location Brussels, virtual meeting Subject Exchange of views on joint procurement and scientific assessment of Remdesivir Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 07 Dec 2020 Location virtual meeting Subject Exchange of views, update on Remdesivir Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 16 Oct 2020 Location Brussels - virtual meeting Subject Exchange of views - update on Remdesivir Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 09 Sep 2020 Location Phone call Subject Discussions/update on Remdesivir Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 06 Jul 2020 Location Brussels Subject VC meeting: Exchange of views on the forthcoming Pharmaceutical Strategy Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 06 May 2020 Location Brussels Subject VC meeting on remdesivir as a developmental medicine, the clinical trial programme, actions taken in respect of making remdesivir available via a compassionate use, Member States' needs and distribution should it receive market authorisation Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 07 Apr 2020 Location Brussels Subject Discussion on medicines (potential treatments, production, clinical trials, access to results) Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 25 Sep 2017 Location Brussels Subject Hepatitis B and C, HIV Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Arunas Vinciunas (Cabinet member)
-
Date 19 Jun 2017 Location Brussels Subject economic situation within the EU, investment climate, deepening of the EMU, social dimension of the European project, financial regulations and markets Cabinet Cabinet of Vice-President Valdis Dombrovskis Portfolio Euro and Social Dialogue, also in charge of Financial Stability, Financial Services and Capital Markets Union Attending - Valdis Dombrovskis (Vice-President)
- Elina Melngaile (Cabinet member)
Other Lobbyists
- Meetings